RENOVORX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.243 USD | +2.73% |
|
+6.24% | -45.72% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapyâs toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.243
USD
Average target price
3.75
USD
Spread / Average Target
+201.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.72% | 29.77M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RNXT Stock
- News RenovoRx, Inc.
- Roth MKM Adjusts Price Target on RenovoRx to $13 From $14, Maintains Buy Rating
